BioGend Competitors

Stocks . Taiwan . 
Stock . BioGend Therapeutics Co
6733 Stock   37.35  0.48  1.27%   
BioGend Therapeutics competes with Savior Lifetec, Panion BF, Medigen Biotechnology, Taigen Biopharmaceutica, and Sinphar Pharmaceutical; as well as few others. Analyzing BioGend Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of BioGend Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.

BioGend Therapeutics vs Senhwa Biosciences Correlation

Good diversification

The correlation between BioGend Therapeutics Co and 6492 is -0.04 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding BioGend Therapeutics Co and 6492 in the same portfolio, assuming nothing else is changed.

Moving against BioGend Stock

  0.591303 Nan Ya PlasticsPairCorr
  0.441301 Formosa Plastics CorpPairCorr
  0.422882 Cathay Financial HoldingPairCorr
  0.362303 United MicroelectronicsPairCorr
  0.316505 Formosa PetrochemicalPairCorr

BioGend Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BioGend Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of BioGend and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of BioGend Therapeutics does not affect the price movement of the other competitor.

High positive correlations

4157
+ 0.84
6794
4157
+ 0.78
3176
3176
+ 0.74
6794
6492
+ 0.71
4167
4157
+ 0.58
4167
6794
+ 0.48
4167
  

High negative correlations

6875
- 0.52
4167
1734
- 0.5
6794
7754
- 0.46
1760
1734
- 0.43
4157
1734
- 0.4
3176
6492
- 0.38
6875

Risk-Adjusted Indicators

There is a big difference between BioGend Stock performing well and BioGend Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BioGend Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

BioGend Therapeutics Competitive Analysis

The better you understand BioGend Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BioGend Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BioGend Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
6733 4167 6794 1760 7754 3176 4157 1734 6875 6492
 1.27 
 37.35 
BioGend
 3.45 
 21.00 
Savior
 1.71 
 89.10 
UnicoCell
 0.45 
 67.60 
Panion
 1.01 
 50.20 
7754
 2.67 
 32.85 
Medigen
 2.69 
 14.45 
Taigen
 0.48 
 31.30 
Sinphar
 3.33 
 45.00 
Pharmosa
 2.24 
 61.10 
Senhwa
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Not too volatile
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Weakest
Good
Solid
Soft
Mild
Fair
Solid
Weak
Weakest
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Unknown
Low
Unknown
Low
Unknown
Small
Fair
Small
Unknown
Small
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Fairly Valued
Under Valued
Fairly Valued
Fairly Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Sell
Strong Buy
Cautious Hold
Strong Hold
Strong Sell
Strong Buy
Cautious Hold
Strong Sell
Strong Hold
Current Ratio
N/A
1.96
N/A
1.5
N/A
N/A
N/A
2.25
N/A
38.14
Net Asset
N/A
4.54 B
N/A
2.95 B
N/A
8.2 B
1.39 B
6.22 B
N/A
N/A
Profit Margin
N/A
0.0354
N/A
0.11
N/A
-0.0804
N/A
0.0725
N/A
N/A
EBITDA
N/A
266.47 M
N/A
340.96 M
N/A
1.35 B
905.1 M
109.64 M
N/A
(373.96 M)
Operating Margin
N/A
-0.0745
N/A
0.17
N/A
0.0172
-9.4
0.0747
N/A
N/A
Current Valuation
N/A
5.13 B
N/A
15.29 B
N/A
2.9 B
11.41 B
6.26 B
N/A
9.33 B
Price To Book
N/A
1.76
N/A
7.27
N/A
2.01
11.51
1.88
N/A
5.03
Retained Earnings
N/A
N/A
N/A
N/A
N/A
N/A
N/A
237 M
N/A
N/A
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
2.28 B
N/A
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.48
N/A
N/A
Beta
N/A
0.6
N/A
0.52
N/A
0.99
0.93
0.79
N/A
0.42
Number Of Employees
N/A
384
N/A
16
N/A
18
23
26
N/A
9
Shares Outstanding
N/A
317.03 M
N/A
85.74 M
N/A
139.45 M
716.84 M
167.72 M
N/A
89.62 M
Cash Flow From Operations
N/A
(168.34 M)
N/A
401.23 M
N/A
518.12 M
629.07 M
135.54 M
N/A
(286.34 M)
Annual Yield
N/A
0.0068
N/A
0.0088
N/A
N/A
N/A
0.0063
N/A
N/A
Total Debt
N/A
523.67 M
N/A
116.07 M
N/A
470.77 M
N/A
1.49 B
N/A
17.59 M
Return On Equity
N/A
0.0142
N/A
0.14
N/A
-0.0022
-0.21
0.0444
N/A
-25.12
Z Score
N/A
7.2
N/A
75.0
N/A
5.4
N/A
1.8
N/A
N/A
Return On Asset
N/A
-0.0138
N/A
0.0805
N/A
0.0036
-0.15
0.0207
N/A
-15.79
Book Value Per Share
N/A
10.69
N/A
24.55
N/A
18.24
1.5
17.41
N/A
24.95
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
999 M
N/A
N/A
Total Asset
N/A
4.54 B
N/A
2.95 B
N/A
8.2 B
1.39 B
6.22 B
N/A
N/A
Debt To Equity
N/A
93.9
N/A
0.93
N/A
N/A
N/A
51.5
N/A
0.008
Target Price
N/A
N/A
N/A
106.0
N/A
N/A
N/A
N/A
N/A
N/A
Last Dividend Paid
N/A
N/A
N/A
1.5
N/A
N/A
N/A
0.2
N/A
N/A
Shares Owned By Institutions
N/A
4.33
N/A
0.68
N/A
2.8
24.94
1.49
N/A
1.0
Market Capitalization
N/A
6.75 B
N/A
14.53 B
N/A
4.42 B
11.33 B
5.4 B
N/A
11.25 B
Price To Earning
N/A
N/A
N/A
N/A
N/A
N/A
N/A
536.84
N/A
N/A
Price To Sales
N/A
6.23
N/A
6.42
N/A
1.66
369.99
2.15
N/A
N/A
Net Income
N/A
9.96 M
N/A
104.4 M
N/A
(52.61 M)
775.62 M
(38.13 M)
N/A
(358.44 M)
Earnings Per Share
N/A
0.14
N/A
3.15
N/A
-0.5
1.08
1.18
N/A
-4.38
Shares Owned By Insiders
N/A
22.55
N/A
33.64
N/A
25.17
35.93
20.27
N/A
29.79
Revenue
N/A
1.74 B
N/A
1.9 B
N/A
3.92 B
1.29 B
2.43 B
N/A
600 K
Working Capital
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.28 B
N/A
N/A
Cash And Equivalents
N/A
285.72 M
N/A
350.7 M
N/A
N/A
N/A
937.43 M
N/A
2.21 B
Cash Per Share
N/A
1.15
N/A
4.57
N/A
N/A
N/A
5.59
N/A
24.67
Gross Profit
N/A
307.87 M
N/A
912.14 M
N/A
2.55 B
1.28 B
888.71 M
N/A
351 K
Day Typical Price
37.55
21.33
88.9
67.97
49.87
33.5
14.83
31.35
45.4
60.6
Accumulation Distribution
5673.42
290990.0
2163.03
11588.49
6272.03
50797.76
712371.0
2430.77
26156.82
136472.0
Daily Balance Of Power
(0.60)
(0.47)
0.75
0.1579
0.3571
(0.37)
(0.35)
0.6
(0.70)
(0.33)
Period Momentum Indicator
(0.48)
(0.75)
1.5
0.3
0.5
(0.90)
(0.40)
0.15
(1.55)
(1.40)
Rate Of Daily Change
0.99
0.97
1.02
1.0
1.01
0.97
0.97
1.0
0.97
0.98
Day Median Price
37.65
21.5
88.8
68.15
49.7
33.83
15.02
31.38
45.6
60.35
Price Action Indicator
(0.54)
(0.87)
1.05
(0.40)
0.75
(1.42)
(0.78)
N/A
(1.37)
0.05
Relative Strength Index
40.8
64.09
62.36
58.31
N/A
55.84
61.5
54.33
36.28
75.79
Coefficient Of Variation
(557.15)
556.56
441.02
2313.02
1337.23
1157.61
413.49
7135.91
(1,111)
571.45
Mean Deviation
1.14
1.44
1.29
1.05
1.95
1.22
2.44
0.5069
1.82
1.96
Jensen Alpha
(0.27)
0.3719
0.4032
0.0397
0.2041
0.152
0.7089
0.0034
(0.24)
0.4969
Total Risk Alpha
(0.38)
0.1706
0.264
(0.08)
(0.06)
(0.01)
0.4838
(0.06)
(0.48)
0.249
Sortino Ratio
N/A
0.1761
0.2665
(0.01)
0.0858
0.0487
0.3161
(0.1)
N/A
0.1735
Downside Variance
N/A
2.53
1.97
1.34
4.25
2.77
4.94
0.4228
N/A
6.65
Standard Deviation
1.38
1.98
1.98
1.45
3.37
1.81
3.22
0.7304
2.64
2.99
Kurtosis
(0.40)
1.94
7.74
2.59
16.67
4.11
1.14
5.6
3.42
4.04
Potential Upside
1.69
4.07
3.02
2.58
3.37
3.3
7.53
0.9983
3.17
5.7
Treynor Ratio
(1.06)
(0.83)
0.8035
0.2623
0.4158
(1.57)
0.8482
(0)
1.67
2.13
Maximum Drawdown
5.37
8.45
13.5
7.56
22.67
11.21
16.13
4.85
17.4
10.0
Variance
1.92
3.9
3.91
2.11
11.34
3.26
10.34
0.5334
6.96
8.91
Market Risk Adjusted Performance
(1.05)
(0.82)
0.8135
0.2723
0.4258
(1.56)
0.8582
0.0051
1.68
2.14
Risk Adjusted Performance
(0.13)
0.1384
0.173
0.0367
0.0628
0.0694
0.1856
0.0102
(0.06)
0.1362
Skewness
(0.24)
0.9519
1.89
1.27
3.33
1.14
0.8848
1.36
0.7034
1.03
Semi Deviation
N/A
1.21
0.9266
1.04
1.77
1.47
1.75
0.5917
N/A
1.96
Information Ratio
(0.23)
0.1418
0.1889
(0.01)
0.0525
0.0449
0.2186
(0.09)
(0.12)
0.1499
Value At Risk
(2.41)
(2.72)
(1.91)
(1.85)
(3.14)
(2.67)
(2.79)
(0.98)
(3.56)
(3.03)
Expected Short fall
N/A
(1.80)
(1.63)
(1.34)
(2.47)
(1.28)
(3.20)
(0.58)
N/A
(2.18)
Downside Deviation
N/A
1.59
1.4
1.16
2.06
1.66
2.22
0.6503
N/A
2.58
Semi Variance
N/A
1.47
0.8586
1.09
3.15
2.16
3.07
0.3501
N/A
3.86

BioGend Therapeutics Competition Performance Charts

Five steps to successful analysis of BioGend Therapeutics Competition

BioGend Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by BioGend Therapeutics in relation to its competition. BioGend Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of BioGend Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BioGend Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to BioGend Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your BioGend Therapeutics position

In addition to having BioGend Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Money Funds Thematic Idea Now

Money Funds
Money Funds Theme
Funds or Etfs that invest most if their asset in companies from financial sector such as commercial banks, insurance companies, investment funds, and real estate. The Money Funds theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for BioGend Stock Analysis

When running BioGend Therapeutics' price analysis, check to measure BioGend Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioGend Therapeutics is operating at the current time. Most of BioGend Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioGend Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioGend Therapeutics' price. Additionally, you may evaluate how the addition of BioGend Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY